Table 4.

Analysis of P-glycoprotein expression and function in the homozygous vs the heterozygous allelic variants of the MDR1 gene at time of relapse/refractory disease

GG or TTGTP value
MDR   
MRK16    
 Median 1.54 2.14 .15 
 Range 1.02-5.45 1.18-5.55  
 N 13 17  
MRK16/CD34    
 Median 1.88 2.68 .22 
 Range 1.49-4.90 1.46-9.6  
 N  
UIC2    
 Median 1.56 2.28 .22 
 Range 1.12-6.39 0.99-5.24  
 N 13 17  
UIC2/CD34    
 Median 1.67 2.72 .10 
 Range 0.86-7.34 1.69-5.15  
 N  
PSC/Rho    
 Median 1.08 1.14 .30 
 Range 0.81-1.85 0.84-2.19  
 N 13 17  
PSC/Rho/CD34    
 Median 1.21 1.42 .40 
 Range 1.07-1.72 0.82-3.26  
 N  
GG or TTGTP value
MDR   
MRK16    
 Median 1.54 2.14 .15 
 Range 1.02-5.45 1.18-5.55  
 N 13 17  
MRK16/CD34    
 Median 1.88 2.68 .22 
 Range 1.49-4.90 1.46-9.6  
 N  
UIC2    
 Median 1.56 2.28 .22 
 Range 1.12-6.39 0.99-5.24  
 N 13 17  
UIC2/CD34    
 Median 1.67 2.72 .10 
 Range 0.86-7.34 1.69-5.15  
 N  
PSC/Rho    
 Median 1.08 1.14 .30 
 Range 0.81-1.85 0.84-2.19  
 N 13 17  
PSC/Rho/CD34    
 Median 1.21 1.42 .40 
 Range 1.07-1.72 0.82-3.26  
 N  

For P-gp expression, the monoclonal antibodies MRK16 and UIC2 were used; for P-gp function, the PSC/Rho 123 retention ratio was used. In samples with more than 10% CD34 expression, the variables were also evaluated in the CD34+ subfraction of the blasts. TheP values indicate the differences between the homozygous and heterozygous patients.

or Create an Account

Close Modal
Close Modal